DIM — Sartorius Stedim Biotech SA Income Statement
0.000.00%
Last trade - 00:00
- €18.49bn
- €20.98bn
- €2.78bn
R2019 December 31st | R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,441 | 1,910 | 2,887 | 3,493 | 2,776 |
Cost of Revenue | |||||
Gross Profit | 748 | 1,003 | 1,553 | 1,835 | 1,234 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1,109 | 1,438 | 2,022 | 2,498 | 2,327 |
Operating Profit | 332 | 472 | 865 | 995 | 449 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 317 | 461 | 647 | 1,130 | 401 |
Provision for Income Taxes | |||||
Net Income After Taxes | 236 | 339 | 414 | 880 | 312 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 235 | 336 | 414 | 876 | 310 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 235 | 336 | 414 | 876 | 310 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 2.82 | 3.9 | 4.68 | 9.9 | 4.32 |
Dividends per Share |